Trial Profile
A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON-HODGKIN'S LYMPHOMA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CONTRALTO
- Sponsors AbbVie; Roche
- 12 Aug 2020 Results published in the Blood.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.